论文部分内容阅读
目的:探讨阿奇霉素联合痰热清治疗小儿肺炎支原体肺炎(mycoplasma pneumoniae pneumonia,MPP)的临床疗效。方法:124例MPP患儿随机分为对照组(56例)与治疗组(68例),其中对照组给予阿奇霉素序贯治疗,治疗组则在此基础上另外给予痰热清治疗。采用双抗体夹心ELISA法、免疫比浊法分别检测治疗前后所有MPP患儿血清CRP、IL-6与TNF-α含量。同时观察比较两组临床疗效、症状体征及不良反应情况。结果:①经治疗所有患儿血清CRP、IL-6与TNF-α浓度均明显下降(P<0.01),治疗组与对照组间差异无统计学意义(P>0.05)。②治疗组总有效率为97.06%,显著高于对照组83.93%的总有效率(P<0.05)。③治疗组退热时间,咳嗽和肺啰音消失时间均显著短于对照组(P<0.05)。④治疗组不良反应发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论:痰热清联合阿奇霉素序贯疗法治疗小儿MPP安全有效,值得进一步推广。
Objective: To investigate the clinical efficacy of azithromycin combined with Tanreqing in treating children with mycoplasma pneumoniae pneumonia (MPP). Methods: A total of 124 children with MPP were randomly divided into control group (n = 56) and treatment group (n = 68). The control group received azithromycin sequential treatment. The treatment group received additional Tanreqing treatment. The contents of CRP, IL-6 and TNF-α in serum of all MPP children before and after treatment were detected by double antibody sandwich ELISA and immunoturbidimetry respectively. At the same time observe and compare the clinical efficacy, symptoms and signs and adverse reactions. Results: ① The serum levels of CRP, IL-6 and TNF-α were significantly decreased in all the treated children (P <0.01). There was no significant difference between the treatment group and the control group (P> 0.05). ② The total effective rate in the treatment group was 97.06%, significantly higher than that in the control group 83.93% (P <0.05). The treatment group fever time, cough and pulmonary rales disappeared significantly shorter than the control group (P <0.05). ④ The incidence of adverse reactions in the treatment group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion: Tanreqing combined with azithromycin sequential therapy for children with MPP safe and effective, worth further promotion.